@article{6851,
  author = {B. Yetkin-Arik and S. A. Jansen and S. Varderidou-Minasian and B. Westendorp and K.-P. Skarp and M. Altelaar and C. A. Lindemans and M. J. Lorenowicz},
  title = {Mesenchymal stromal/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage},
  abstract = {Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for leukemia and a range of non-malignant disorders. The success of the therapy is hampered by occurrence of acute graft-versus-host disease (aGvHD); an inflammatory response damaging recipient organs, with gut, liver, and skin being the most susceptible. Intestinal GvHD injury is often a life-threatening complication in patients unresponsive to steroid treatment. Allogeneic mesenchymal stromal/stem cell (MSC) infusions are a promising potential treatment for steroid-resistant aGvHD. Data from our institution and others demonstrate rescue of approximately 40–50% of aGvHD patients with MSCs in Phase I, II studies and minor side effects. Although promising, better understanding of MSC mode of action and patient response to MSC-based therapy is essential to improve this lifesaving treatment.},
  year = {2024},
  journal = {Stem Cell Research & Therapy},
  volume = {15},
  pages = {125},
  month = {2024-04-29},
  issn = {1757-6512},
  url = {https://doi.org/10.1186/s13287-024-03738-9},
  doi = {10.1186/s13287-024-03738-9},
  language = {en},
}